A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109

Trial Profile

A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 43 to 18 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Jun 2010 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top